ASKER Asker Healthcare Group AB (publ)
Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care. The company supplies and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products. In addition, it develops and sells disposable medical supplies under the Evercare, Selefa, and Embra brands; distributes eye surgery products; and develops and sells products for time-management, communication, and cognition for schools, assistive technology centres, and other public services. Further, the company provides support and assistance to people needing wound, diabetes, and urological care; ostomy, urology, and rehab services; ambulance services; and products for physiotherapy practices, as well as supplies exercise and treatment equipment and measurement. Additionally, it sells and rents out various mobility aids and rehab products, such as pressure-relieving mattresses and cushions, as well as manufactures and distributes pressure care products. The company operates in Sweden, Norway, Finland, Estonia, Latvia, Lithuania, Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, France, Slovakia, Czech Republic, and Poland. Asker Healthcare Group AB (publ) was founded in 2006 and is headquartered in Danderyd, Sweden.…
Industry Peers
Medical DistributionKey Statistics
About Asker Healthcare Group (STO: ASKER)
›
Asker Healthcare Group (STO: ASKER) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 4,898 employees.
The shares were at 71.25 SEK on 20 November 2026, down 23.3% over 52 weeks. Its 52-week range is 56.20 SEK to 94.16 SEK: the price is 24.3% below the high and 26.8% above the low.
At a market capitalisation of 27.58B SEK, it trades at 36.4 times trailing earnings and 20.9 times forward earnings. The median trailing P/E of its 17 largest Medical Distribution peers is 20.3, a premium of 79% for ASKER. It pays a dividend yielding 0.55% (it pays out 20% of its earnings), against a median of 2.55% among the dividend payers in that peer group.
Asker Healthcare Group reports return on equity of 7.5%, an operating margin of 6.7% and revenue up 15.2% year over year.
Its debt exceeds its cash by 6.17B SEK, a debt-to-equity ratio of 0.89. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 92.10 SEK is 29.3% above the current price. The next earnings report is expected on 10 February 2027.